Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May;9(5):433-45.
doi: 10.1586/17474086.2016.1158096. Epub 2016 Mar 17.

Acute myeloid leukemia: advancing clinical trials and promising therapeutics

Naval Daver  1 , Jorge Cortes  1 , Hagop Kantarjian  1 , Farhad Ravandi  1
Affiliations
Review

Acute myeloid leukemia: advancing clinical trials and promising therapeutics

Naval Daver et al. Expert Rev Hematol. 2016 May.

Abstract

Recent progress in understanding the biology of acute myeloid leukemia (AML) and the identification of targetable driver mutations, leukemia specific antigens and signal transduction pathways has ushered in a new era of therapy. In many circumstances the response rates with such targeted or antibody-based therapies are superior to those achieved with standard therapy and with decreased toxicity. In this review we discuss novel therapies in AML with a focus on two major areas of unmet need: (1) single agent and combination strategies to improve frontline therapy in elderly patients with AML and (2) molecularly targeted therapies in the frontline and salvage setting in all patients with AML.

Keywords: AML; clinical trials; molecular therapy; monoclonal antibodies; multikinase inhibitors.

PubMed Disclaimer

Conflict of interest statement

Financial and competing interests disclosure: The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010 Jan 21;115(3):453–74. - PubMed
    1. Schiffer CA. Hematopoietic growth factors and the future of therapeutic research on acute myeloid leukemia. The New England journal of medicine. 2003 Aug 21;349(8):727–9. - PubMed
    1. Kantarjian HM. Therapy for elderly patients with acute myeloid leukemia: a problem in search of solutions. Cancer. 2007 Mar 15;109(6):1007–10. - PubMed
    1. Kantarjian H, O’Brien S, Cortes J, Giles F, Faderl S, Jabbour E, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006 Mar 1;106(5):1090–8. - PubMed
    1. Nazha A, Ravandi F. Acute myeloid leukemia in the elderly: do we know who should be treated and how? Leukemia & lymphoma. 2014 May;55(5):979–87. - PMC - PubMed

MeSH terms

Substances